Exact Sciences: Great Company But Most of the Upside Is Behind It
publication date: Jun 7, 2019
Image Source: Exact Sciences Corp -- IR Presentation. Exact Sciences operates as a molecular diagnostics company built around its Cologuard offering, which was approved by the US FDA in August 2014. While Exact Sciences stock has performed very well since 2016, the risk-reward trade off isn’t great as things stand today now that shares have zoomed from the single-digits in 2016 to roughly $105 per share as of this writing.
This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!